Contraline

Contraline is pioneering the first major innovations in male contraception since the vasectomy, addressing a significant and long-standing gap in reproductive health. The company's pipeline features two distinct product candidates: NES/T, a daily topical gel, and ADAM, a long-acting implant, both aimed at providing reversible sperm suppression. With its lead gel having reportedly completed clinical trials in 2025, Contraline is positioned as a frontrunner in a nascent but high-potential market. The company is backed by experienced leadership, a strong scientific advisory board, and venture capital, aiming to bring much-needed choice and equity to contraceptive responsibility.

Localized, reversible drug delivery platform for male contraception, utilizing topical and implantable formats to suppress sperm production.

The competitive landscape for novel male contraceptives is currently sparse, with no FDA-approved hormonal or long-acting reversible options beyond condoms and vasectomy. Contraline appears to be a frontrunner with its late-stage gel. Potential future competitors include other biotechs exploring hormonal gels, pills, or implants, but significant barriers to entry in clinical development and regulation remain high.